Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Recommendation of "Moderate Buy" from Brokerages

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $33.00.

AVTX has been the topic of several research analyst reports. HC Wainwright reiterated a "neutral" rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Wedbush reaffirmed an "outperform" rating and set a $18.00 target price on shares of Avalo Therapeutics in a report on Thursday, March 20th. BTIG Research started coverage on shares of Avalo Therapeutics in a research report on Thursday, December 19th. They issued a "buy" rating and a $40.00 price target on the stock. Jefferies Financial Group began coverage on shares of Avalo Therapeutics in a research report on Tuesday. They set a "buy" rating and a $23.00 price objective for the company. Finally, Stifel Nicolaus assumed coverage on shares of Avalo Therapeutics in a report on Tuesday. They issued a "buy" rating and a $36.00 target price on the stock.

Avalo Therapeutics Price Performance

Shares of NASDAQ AVTX traded down $0.27 during mid-day trading on Tuesday, reaching $8.46. 36,738 shares of the company traded hands, compared to its average volume of 72,453. Avalo Therapeutics has a fifty-two week low of $5.99 and a fifty-two week high of $22.47. The stock has a fifty day simple moving average of $7.62 and a 200-day simple moving average of $9.13.

Remove Ads

Institutional Trading of Avalo Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. RA Capital Management L.P. purchased a new position in shares of Avalo Therapeutics in the third quarter worth approximately $9,186,000. Ikarian Capital LLC boosted its stake in Avalo Therapeutics by 1,673.0% in the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company's stock worth $9,218,000 after purchasing an additional 915,629 shares during the period. Northern Trust Corp purchased a new position in Avalo Therapeutics during the 4th quarter worth approximately $168,000. Velan Capital Investment Management LP purchased a new position in Avalo Therapeutics during the 4th quarter worth approximately $817,000. Finally, Tower Research Capital LLC TRC raised its stake in Avalo Therapeutics by 998.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock valued at $31,000 after purchasing an additional 3,754 shares during the period. Institutional investors and hedge funds own 87.06% of the company's stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.